أعرض في EDS

Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy

التفاصيل البيبلوغرافية
العنوان: Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy
المؤلفون: Alain C. Mita, Alice S. Bexon, Maria Regina C. Flores, Donald A. Richards, Paul Conkling, Guillaume de La Bourdonnaye, David S. Wages, Thomas E. Boyd, David Smith, John Nemunaitis
المصدر: Lung Cancer. 77:S39
بيانات النشر: Elsevier BV, 2012.
سنة النشر: 2012
مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Agonist, Cancer Research, medicine.medical_specialty, Chemotherapy, Bevacizumab, medicine.drug_class, business.industry, medicine.medical_treatment, non-small cell lung cancer (NSCLC), TLR9, medicine.disease, Internal medicine, medicine, In patient, Erlotinib, business, medicine.drug
تدمد: 0169-5002
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c952c4cdae82d8986b537447a8a77d7cTest
https://doi.org/10.1016/j.lungcan.2012.05.076Test
حقوق: CLOSED
رقم الانضمام: edsair.doi...........c952c4cdae82d8986b537447a8a77d7c
قاعدة البيانات: OpenAIRE
الوصف
تدمد:01695002